Biogen BIIB

NAS: BIIB | ISIN: US09062X1037   30/04/2025
121,08 USD (+0,76%)
(+0,76%)   30/04/2025

16 april 2025 · Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union · Persbericht

2 april 2025 · Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease · Persbericht

24 maart 2025 · Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square · Persbericht

11 maart 2025 · Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients · Persbericht

18 februari 2025 · Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments · Persbericht

31 januari 2025 · Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union · Persbericht

27 januari 2025 · FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease · Persbericht

23 januari 2025 · FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA · Persbericht

14 januari 2025 · FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease · Persbericht

19 november 2024 · Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity · Persbericht

14 november 2024 · Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease · Persbericht

31 oktober 2024 · Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference · Persbericht

29 oktober 2024 · Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases · Persbericht

29 oktober 2024 · Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer · Persbericht

28 oktober 2024 · Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 · Persbericht

27 oktober 2024 · Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 · Persbericht

24 oktober 2024 · Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference · Persbericht

22 oktober 2024 · Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024 · Persbericht

9 oktober 2024 · Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients · Persbericht

8 oktober 2024 · New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA · Persbericht

Mijn selecties